VIP Research Guide (Preclinical Overview)
Vasoactive Intestinal Peptide (VIP) serves as a critical signaling neuropeptide across neuroendocrine, immunomodulatory, and gastrointestinal research models. This comprehensive VIP research guide outlines its structural chemistry, receptor kinetics, preclinical assay protocols, and necessary analytical purity standards for laboratory investigation.
Quick answer
Vasoactive Intestinal Peptide (VIP) serves as a critical signaling neuropeptide across neuroendocrine, immunomodulatory, and gastrointestinal research models. This comprehensive VIP research guide outlines its structural chemistry, receptor kinetics, preclinical assay protocols, and necessary analytical purity standards for laboratory investigation.
Key takeaways
- Vasoactive Intestinal Peptide (VIP) is a highly conserved 28-amino acid neuropeptide originally isolated from porcine duodenum in 1970.
- VIP exerts its biological actions primarily through two class B G-protein coupled receptors: VPAC1 and VPAC2.
- In neuroimmunological assays, VIP acts as a potent endogenous modulator of innate and adaptive immune cell signaling.
- Originally identified for its profound vasodilatory properties, VIP plays a central role in non-adrenergic, non-cholinergic (NANC) neurotransmission across vascular and non-vascular smooth muscle preparations.
1. Structural Chemistry and Discovery of Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide (VIP) is a highly conserved 28-amino acid neuropeptide originally isolated from porcine duodenum in 1970. Structurally belonging to the secretin/glucagon superfamily of peptide hormones, VIP features a basic amphipathic alpha-helical conformation in solution that facilitates high-affinity interaction with its target membrane receptors. Its primary sequence—His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn—is identical across almost all mammalian species studied to date, emphasizing its evolutionary importance.
In basic biochemical research, VIP is synthesized via solid-phase peptide synthesis (SPPS) to yield a precise monomeric chain with a C-terminal amide. Researchers examining structural biology often evaluate VIP research peptides to explore secondary structure transitions in fluorinated solvents or lipid membrane environments. Because the single methionine residue at position 17 is prone to oxidation in non-inert environments, analytical verification of sequence integrity remains vital prior to initiating in vitro binding assays.
2. Receptor Kinase Interactions and Signaling Cascades
VIP exerts its biological actions primarily through two class B G-protein coupled receptors: VPAC1 and VPAC2. Both receptors exhibit high nanomolar-to-picomolar affinity for VIP and are widely expressed across central nervous system tissues, immune cell subpopulations, and peripheral vascular smooth muscle preparations. Additionally, VIP demonstrates weak affinity for the PAC1 receptor, which is predominantly selective for pituitary adenylate cyclase-activating polypeptide.
Upon ligand binding to VPAC1 or VPAC2, the receptor undergoes a conformational shift that stimulates membrane-bound adenylyl cyclase via the Gs alpha subunit. This activation triggers an intracellular surge of cyclic adenosine monophosphate (cAMP), subsequently activating protein kinase A (PKA) and downstream transcription factors such as cAMP response element-binding protein (CREB). Preclinical studies suggest that this signaling axis regulates cellular differentiation, cytokine transcription profiles, and ion channel conductances in diversas cell lines. Detailed receptor binding maps and kinetic models are cataloged within the PX1 Research library for comparative receptor pharmacology.
3. Neuroimmunology and Inflammatory Preclinical Models
In neuroimmunological assays, VIP acts as a potent endogenous modulator of innate and adaptive immune cell signaling. In vitro data indicate that VIP downregulates the production of pro-inflammatory cytokines—including TNF-alpha, IL-6, and IL-12—in lipopolysaccharide (LPS)-stimulated macrophages and microglia. Concurrently, VIP upregulates anti-inflammatory signaling mediators such as IL-10, demonstrating a capacity to bias macrophage polarization from an M1 pro-inflammatory phenotype toward an M2 regulatory profile.
Rodent models of neuroinflammation and systemic inflammatory response syndrome (SIRS) frequently utilize VIP to evaluate survival parameters and tissue-specific oxidative stress markers. In these animal studies, VIP administration is observed to attenuate microglial activation, reduce nuclear factor kappa B (NF-kB) translocation, and preserve blood-brain barrier integrity during induced inflammatory insults. Investigation into these signaling networks provides valuable insight into peptide-mediated immunomodulation.
4. Gastrointestinal, Vascular, and Smooth Muscle Dynamics
Originally identified for its profound vasodilatory properties, VIP plays a central role in non-adrenergic, non-cholinergic (NANC) neurotransmission across vascular and non-vascular smooth muscle preparations. In isolated arterial ring assays and gut motility models, VIP induces smooth muscle relaxation through a dual mechanism involving direct cAMP-mediated PKA activation and intracellular calcium sequestration, as well as stimulating nitric oxide (NO) synthase in endothelial cells.
In epithelial tissue models, VIP stimulates mucosal ion and fluid secretion. In vitro chamber experiments utilizing intestinal epithelial monolayers show that VIP application increases transepithelial short-circuit current via chloride ion secretion. These findings make VIP a foundational tool for laboratories investigating mucosal biology, cystic fibrosis transmembrane conductance regulator (CFTR) dynamics, and autonomic regulation of exocrine secretions.
5. Comparative Analysis: VIP, PACAP-38, Secretin, and Exenatide
When designing comparative pharmacological assays within the secretin/glucagon superfamily, selecting the appropriate peptide control is essential for establishing receptor selectivity. VIP shares structural homology and overlapping receptor profiles with several key neuropeptides and incretin mimetics.
While VIP displays dual high affinity for both VPAC1 and VPAC2, PACAP-38 exhibits equivalent affinity for VPAC1 and VPAC2 but unique high affinity for the PAC1 receptor, making it a critical comparator in receptor mapping experiments. Conversely, secretin acts selectively on the secretin receptor with minimal cross-reactivity at VPAC sites despite sharing sequence homology. When contrasting these neuropeptides with metabolic regulators like exenatide, which targets the GLP-1 receptor, researchers can delineate downstream intracellular cascades ranging from cAMP/PKA signaling to metabolic flux alteration. Evaluating these compounds side-by-side clarifies subtle differences in receptor-ligand kinetics.
6. Analytical Purity Standards: HPLC, MS, and Endotoxin Limits
Preclinical investigation requires research compounds of strict chemical purity to ensure experimental reproducibility and eliminate confounding variables. Impurities such as truncated peptide sequences, un-deprotected side chains, or residual organic solvents can alter receptor binding kinetics or induce non-specific cellular toxicity in cell culture models.
To guarantee experimental consistency, PX1 Research Subjects every batch of VIP to rigorous analytical testing. Chemical purity is verified via High-Performance Liquid Chromatography (HPLC) to ensure a minimum of 98% purity, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular weight matching theoretical values. Furthermore, because VIP is frequently evaluated in immunological and cell culture assays, endotoxin levels are verified using Limulus Amebocyte Lysate (LAL) testing to ensure levels remain below strictly defined thresholds (<0.01 EU/μg).
7. Reconstitution Protocols and Solvent Compatibility for Laboratory Use
Lyophilized VIP requires careful handling during reconstitution to prevent aggregation, surface adsorption, or chemical degradation. Because VIP contains basic amino acid residues and a hydrophobic core, proper solvent selection depends on the intended analytical assay.
For standard cell culture and biochemical assays, lyophilized VIP should be reconstituted in sterile, deaerated bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4). If working with ultra-low concentrations (nanomolar or sub-nanomolar ranges), inclusion of a carrier protein such as 0.1% Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA) is strongly recommended to prevent non-specific binding to glass or plastic vessel walls. Reconstitution solutions should be gently swirled rather than vortexed to avoid shear stress-induced denaturation.
8. Storage Protocols and Chemical Stability Optimization
In its original lyophilized form, VIP stored at -20°C or -80°C remains chemically stable for extended periods when kept desiccated and protected from light. Exposure to atmospheric moisture can accelerate peptide hydrolysis and methionine oxidation.
Once reconstituted into aqueous solution, aliquots should be prepared immediately to avoid repeated freeze-thaw cycles, which induce physical aggregation and loss of biological activity. Reconstituted stock solutions stored at -80°C are generally stable for several months, whereas working solutions stored at 4°C should be utilized within 24 to 48 hours. Using nitrogen-overlay techniques during aliquot dispensing can further minimize oxidation of the Met-17 residue.
9. Institutional Sourcing and Laboratory Procurement
Acquiring high-purity neuropeptides for institutional research requires transparent supplier metrics, lot-specific documentation, and domestic supply chain reliability. PX1 Research synthesizes peptides in modern, USA-based facilities operating under strict Quality Management Systems (QMS) compliant with ISO 17025 and cGMP standards.
Principal investigators and laboratory managers requiring high volume or continuous supply for longitudinal animal studies can establish dedicated accounts via our portal for bulk laboratory orders. Every shipment includes a lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms, mass spectra, and endotoxin assay results, ensuring full traceability from synthesis to experimental application.
Frequently Asked Questions
What is the primary receptor affinity profile for VIP in preclinical models?
VIP binds with high picomolar-to-nanomolar affinity to both VPAC1 and VPAC2 receptors, both of which are class B G-protein coupled receptors that stimulate adenylyl cyclase and elevate intracellular cAMP.
How is VIP supplied and shipped by PX1 Research?
VIP is supplied as a lyophilized (freeze-dried) powder in sealed laboratory vials. Orders are shipped directly from California and Arizona facilities with same-day dispatch for orders placed Monday through Friday before standard cut-off times.
What solvents are recommended for reconstituting lyophilized VIP?
Lyophilized VIP should be reconstituted using sterile water for injection or sterile PBS (pH 7.4). For ultra-low concentration work, adding 0.1% BSA helps prevent non-specific peptide binding to vessel walls.
How does PX1 Research verify the purity of VIP lots?
Each lot undergoes rigorous third-party analytical testing, including High-Performance Liquid Chromatography (HPLC) to confirm ≥98% chemical purity and Mass Spectrometry (MS) to verify exact molecular weight.
Why is endotoxin testing critical for VIP research compounds?
Because VIP is often studied in immune cell and neuroinflammatory models, background bacterial endotoxins (LPS) can invalidate assay results by artificially activating immune pathways. PX1 verifies endotoxin levels via LAL assays to ensure strict purity.
What are the recommended storage conditions for reconstituted VIP stock solutions?
Reconstituted stock solutions should be divided into single-use aliquots and stored at -80°C to minimize degradation and avoid repeated freeze-thaw cycles. Protect solutions from light and atmospheric oxygen.
Is VIP suitable for use in human therapeutic protocols?
No. VIP provided by PX1 Research is strictly designated as a research compound for in vitro, cellular, and animal laboratory investigation only. It is not for human, clinical, or therapeutic use.
How can academic and institutional laboratories order bulk quantities of VIP?
Institutional purchasers can request custom quotes and set up specialized lab accounts through the PX1 wholesale procurement program, ensuring consistent batch availability and lot-reservation options.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.